Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

被引:116
|
作者
Fletcher, CV
Anderson, PL
Kakuda, TN
Schacker, TW
Henry, K
Gross, CR
Brundage, RC
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Expt & Clin Pharmacol, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Dept Infect Dis, Denver, CO 80262 USA
[3] Hennepin Cty Med Ctr, HIV Program, Minneapolis, MN 55415 USA
关键词
antiretroviral therapy; combination therapy; drug concentrations; pharmacokinetics; therapeutic drug monitoring;
D O I
10.1097/00002030-200203080-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To demonstrate the feasibility of a concentration-control led approach to combination antiretroviral therapy, and to compare the virological responses and safety of this strategy versus conventional fixed-close therapy. Design: A prospective, randomized, 52 week, open-label trial of concentration-controlled compared with conventional dose zidovudine, lamivudine, and indinavir therapy conduced in a university-based general clinical research center in the United States. Patients: Forty anti retroviral-naive individuals with plasma HIV-RNA levels > 5000 copies/ml. Interventions: Zidovudine, lamivudine, and indinavir plasma concentrations were measured in all participants. Doses were adjusted in those assigned to concentration-controlled therapy to achieve levels equal to or greater than target values. Main outcome measures: The proportion of patients who achieved the desired drug concentrations, the proportion of patients with HIV-RNA levels < 50 copies/ml at week 52, and safety and tolerance in the concentration-control led versus conventional therapy arms. Results: Significantly more concentration-control led recipients achieved the desired concentration targets for all three drugs: 15 of 16 concentration-controlled recipients compared with nine of 17 conventional recipients (P = 0.017) had HIV-RNA levels < 50 copies/ml at week 52. No difference was observed in the occurrence of drug-related clinical events or laboratory abnormalities between the two treatment arms. Conclusion: Concentration-control led therapy implemented simultaneously for three antiretroviral agents was feasible, as well tolerated as conventional therapy, and resulted in a greater proportion of recipients with HlV-RNA levels < 50 copies/ml after 52 weeks. These findings provide a scientific basis to challenge the accepted practice of administering the same dose of antiretroviral agents to all adults, ignoring the concentrations actually achieved. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:551 / 560
页数:10
相关论文
共 50 条
  • [1] Concentration-controlled zidovudine therapy
    Fletcher, CV
    Acosta, EP
    Henry, K
    Page, LM
    Gross, CR
    Kawle, SP
    Remmel, RP
    Erice, A
    Balfour, HH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) : 331 - 338
  • [2] Intermittent antiretroviral therapy in patients with controlled HIV infection
    Marchou, Bruno
    Tangre, Philippe
    Charreau, Isabelle
    Izopet, Jacques
    Girard, Pierre-Marie
    May, Thierry
    Ragnaud, Jean-Marie
    Aboulker, Jean-Pierre
    Molina, Jean-Michel
    AIDS, 2007, 21 (04) : 457 - 466
  • [3] Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy
    Acosta, EP
    Henry, K
    Page, LM
    Erice, A
    Balfour, HH
    Fletcher, CV
    PHARMACOTHERAPY, 1997, 17 (03): : 424 - 430
  • [4] Antiretroviral therapy for HIV infection
    Lozano, Fernando
    Domingo, Pere
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2011, 29 (06): : 455 - 465
  • [5] A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda
    Reynolds, Steven J.
    Kityo, Cissy
    Hallahan, Claire W.
    Kabuye, Geoffrey
    Atwiine, Diana
    Mbamanya, Frank
    Ssali, Francis
    Dewar, Robin
    Daucher, Marybeth
    Davey, Richard T., Jr.
    Mugyenyi, Peter
    Fauci, Anthony S.
    Quinn, Thomas C.
    Dybul, Mark R.
    PLOS ONE, 2010, 5 (04):
  • [6] Concentration-Controlled or Effect-Controlled TrialsUseful Alternatives to Conventional Dose-Controlled Trials?
    Anders Grahnén
    Mats O. Karlsson
    Clinical Pharmacokinetics, 2001, 40 : 317 - 325
  • [7] Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir
    Kakuda, TN
    Page, LM
    Anderson, PL
    Henry, K
    Schacker, TW
    Rhame, FS
    Acosta, EP
    Brundage, RC
    Fletcher, CV
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) : 236 - 242
  • [8] THE CONCENTRATION-CONTROLLED RECYCLING REACTOR
    LOWE, A
    SCHNITZLEIN, K
    CHEMIE INGENIEUR TECHNIK, 1994, 66 (01) : 57 - 63
  • [9] Concentration-controlled or effect-controlled trials -: Useful alternatives to conventional dose-controlled trials?
    Grahnén, A
    Karlsson, MO
    CLINICAL PHARMACOKINETICS, 2001, 40 (05) : 317 - 325
  • [10] Dual antiretroviral therapy for HIV infection
    Soriano, Vicente
    Vicente Fernandez-Montero, Jose
    Benitez-Gutierrez, Laura
    de Mendoza, Carmen
    Arias, Ana
    Barreiro, Pablo
    Pena, Jose M.
    Labarga, Pablo
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 923 - 932